{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-065073","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.742214+00:00","generated_at":"2026-06-01T08:41:12.008326+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rezolute reports positive Phase 2 results for RZ402 in DME; CST reduced up to ~50 microns","bullets":["Phase 2 study of 94 DME patients met primary endpoints: CST reduction (p=0.02) and good safety profile.","CST improvement up to ~50 microns; 200 mg dose showed largest response; sub-analysis at CST ≥400 showed ~75 micron improvement.","RZ402 safe and well-tolerated; AEs mild and comparable to placebo; no ocular adverse effects typical of intravitreal injections.","No significant BCVA improvement, consistent with study duration; five 200 mg patients (20%) had 1-step DRSS improvement.","Target concentrations exceeded at all three doses (50, 200, 400 mg) supporting once-daily oral dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-065073","json":"https://secwatch.observer/filing/0001104659-24-065073.json","markdown":"https://secwatch.observer/filing/0001104659-24-065073.md","text":"https://secwatch.observer/filing/0001104659-24-065073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924065073/0001104659-24-065073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924065073/tm2415552d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:41:12.008326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}